Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (>=2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was ...
The combination of pelareorep and atezolizumab achieved an objective response rate (ORR) of 30% (six among 20 evaluable patients). This represents a greater than 2x improvement over the historical ...
According to Mordor Intelligence, the global clinical trials market is valued at USD 90.1 billion in 2025 and is projected to ...
Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion of ...
BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing ...
METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally ...
(Reuters) -U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical, deepening their use of artificial intelligence ...
New York, New York--(Newsfile Corp. - October 13, 2025) - Digital Silk, an award-winning agency focused on creating brand strategies, custom websites and digital marketing campaigns, has shared ...
Cracker Barrel has cut ties with the design firm that created its controversial new logo and redesigned restaurants. The restaurant chain started implementing the changes but quickly reversed course ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback